Related Experiment Video
Updated: Jan 5, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
[Mirtazapine-Induced Mania: A Case Report]
Catarina Freitas1, Rui Barranha2, Tânia Abreu2
1Departamento de Psiquiatria e Saúde Mental. Centro Hospitalar de Trás-os-Montes e Alto Douro. Vila Real. Portugal.
Abstract:
Manic and hypomanic states associated with antidepressant treatments are relatively common; however, when specifically considering mirtazapine, those side effects are infrequent. The authors report a clinical case regarding a manic episode with dysphoric features in a patient with no personal or family previous psychiatric history. It began two weeks after starting treatment with mirtazapine up to 30 mg/day. This episode was treated discontinuing mirtazapine and initiating olanzapine (10 mg), with symptomatic remission. Mirtazapine has a specific pharmacodynamics, blocking not only post-synaptic serotonergic receptors but also α2-presynaptic adrenergic receptors. Taking this into consideration, it was hypothesized that this case could be attributed to a noradrenergic syndrome, characterized by dysphoria, irritability, insomnia and psychomotor agitation.
Related Concept Videos
Mania and Antimanic Drugs: Overview
Antidepressant Drugs: MAOIs and Other Agents
Bipolar Disorder
Psychosis: Goals of Pharmacotherapy
Psychosis and Antipsychotic Drugs: Overview
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

